December 15, 2022 (Boston, MA) – Covington Associates, a leading middle market investment bank announced its role as exclusive financial advisor to Commonwealth Informatics, Inc. (Commonwealth), a market-leading provider of cloud-based drug safety analytics products and services for medical research and healthcare delivery, in the sale of its business to Stanley Capital Partners LLP (SCP)-backed portfolio company Qinecsa Solutions UK Ltd. (Qinecsa), a leading provider of pharmacovigilance services and technologies to the global pharmaceutical industry. The financial terms of this transaction were not disclosed.

Headquartered in Massachusetts, USA, Commonwealth, an independently-operated subsidiary of Genpact, is the technology leader in signal management, providing an innovative cloud-based solution that leverages advanced analytics to help clients improve drug safety through end-to-end signal detection and risk management. The firm’s clients include large and medium-sized life science companies, government regulatory agencies, and public health organizations across the US, UK, Europe, and Asia.

The acquisition of Commonwealth provides a significant step for Qinecsa and its clients, toward creating an end-to-end vigilance platform in the market. The combination brings together world-class pharmacovigilance services with a proven and scalable platform for the digital capture, processing, analysis, and reporting of safety data. This transaction also marks Qinecsa’s second acquisition of 2022, following the acquisition of Reportum in April. Reportum is an innovative case intake and digital workflow platform for pharmacovigilance, serving some of the largest businesses across the global pharmaceutical industry.

“We are excited to be adding the Commonwealth Vigilance Workbench to Qinecsa’s portfolio of solutions. We believe the combination of Qinecsa’s scientific expertise in pharmacovigilance, SCP’s strategic support, and Commonwealth’s agile innovation will allow us to significantly strengthen the value we deliver to clients. We look forward continuing our work to improve the safe and effective use of healthcare products worldwide,” said Geoffrey Gordon, President and Co-Founder of Commonwealth.

“The Qinecsa team is very pleased to be welcoming Commonwealth to the organisation. We are excited to work together to integrate leading signal detection software into Qinecsa’s solutions. Our clients, existing and future, will further benefit from the development of our analytical and consultancy services,” said Humaira Qureshi, President of Qinecsa.

“The joining together of Commonwealth and Qinecsa represents a great opportunity for growth in the pharmacovigilance space, and we are proud to be supporting the development of a leader in the market. The acquisition also supports SCP’s strategy of keeping Qinecsa at the forefront of specialist service provision. We look forward to supporting both the Commonwealth and Qinecsa teams in their innovative and important work for leading global organisations,” said Simon Cottle, SCP Founding Partner.

ABOUT COVINGTON ASSOCIATES

Covington Associates is an investment banking firm offering advisory services in the areas of mergers and acquisitions (“M&A”), capital raising and strategic advisory to middle-market companies across the Healthcare, Business Services, Consumer & Industrial, and Technology verticals. Founded in 1991 and based in Boston, the vision for Covington has been to provide clients with the highest caliber of senior-level attention and to remain an advice driven and results focused organization. Since its inception, Covington Associates has completed over 350 transactions globally for both private and publicly traded companies totaling over $30 billion. Further information can be found at http://www.covingtonassociates.com/overview/.

ABOUT COMMONWEALTH INFORMATICS, INC.

Commonwealth Informatics, an independently-operated subsidiary of Genpact, is a technology and services company with industry expertise in medical product safety and public health surveillance. Pharmaceutical and biotechnology companies, government agencies, and healthcare providers use Commonwealth’s products and services to assemble relevant data and answer complex clinical and safety analysis questions quickly and accurately.

Learn more about the innovative products and services that are helping to improve the speed and accuracy of pharmacovigilance evidence generation at https://www.commoninf.com

ABOUT STANLEY CAPITAL PARTNERS LLP

Stanley Capital Partners LLP (SCP) is a fast-growing European-focused mid-market private equity firm with proven expertise in finding and building value, locked up in the growth businesses of tomorrow. The firm brings enhanced efficiency through proprietary research and technology to identify investment opportunities that help deliver lasting transformation in Healthcare, Technology and Resource Efficiency businesses with enterprise values of $250m-2.5bn or more. Founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt, SCP partners with management teams to create value through M&A, operational change, and technology enablement. With a 100+-strong team of professionals, SCP has assets under management of $460m today. Find out more at www.stanley-capital.com

ABOUT QINECSA SOLUTIONS UK

Qinecsa is a trusted partner to global life science companies. We bring together best-in-class technology and scientific expertise to connect life science companies to the right safety solutions. Through our unique insight into the challenges of pharmacovigilance, we have created industry-leading, end-to-end solutions for capturing, managing, and evaluating drug safety data, more efficiently and accurately. Working with life science companies we drive progress to continue protecting lives. Find out more at www.qinecsa.com